Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kissei Pharmaceutical is funding $2.5m to support further clinical development of MediciNova's MN-221 to treat acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
As per the license agreenent signed between the two companies in 2004 agreement, they will share all data and associated know-how of the MN-221 development program.
MN-221 is an intravenous drug which is beta (2)-adrenergic receptor agonist.
MediciNova has completed several Phase 1 and 2a trials and is currently conducting a Phase 2b study in patients with acute exacerbations of asthma.
The Phase 2b data showed improvements in FEV1 in all asthma trials as well as a 45% decrease in the hospitalization rate.
MediciNova also completed a Phase 1b clinical study of MN-221 in patients with stable, moderate to severe COPD in which MN-221 demonstrated clinically significant improvements in FEV1 with no clinically relevant safety concerns.